nitroxyl has been researched along with Cardiac Failure in 17 studies
nitroxyl: hydroxamic acid oxidized to nitroxyl free radical
nitroxyl : A nitrogen oxoacid consisting of an oxygen atom double-bonded to an NH group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Heart failure is the end stage of various heart diseases such as ischemic heart disease, dilated cardiomyopathy, valvular heart disease, congenital heart disease, and hypertensive myocardial damage." | 6.61 | Advances in research on treatment of heart failure with nitrosyl hydrogen. ( An, J; Deng, Y; Guo, Y; Wang, J; Wu, L; Xu, J, 2019) |
| "Nitroxyl (HNO) plays a unique role in cardiovascular physiology by direct post-translational modification of thiol residues on target proteins, specifically SERCA2a, phospholamban, the ryanodine receptor and myofilament proteins in cardiomyocytes." | 6.61 | Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. ( Borentain, M; Cleland, JG; DeSouza, MM; Felker, GM; Kessler, PD; McMurray, JJV; O'Connor, CM; Seiffert, D; Teerlink, JR; Voors, AA, 2019) |
| "Nitroxyl donors have been shown to improve cardiac function in normal and failing dogs, and in isolated cardiomyocytes they increase fractional shortening and Ca(2+) transients, independently from cAMP/PKA or cGMP/PKG signaling." | 6.50 | Nitroxyl (HNO) for treatment of acute heart failure. ( Arcaro, A; Lembo, G; Tocchetti, CG, 2014) |
| "Nitroxyl (HNO) is a reactive nitrogen molecule that has potential therapeutic benefits for patients with acute heart failure." | 5.30 | A Phase 1 Randomized Study of Single Intravenous Infusions of the Novel Nitroxyl Donor BMS-986231 in Healthy Volunteers. ( Cowart, D; Foo, SY; Guptill, JT; Lynch, K; Noveck, RJ; Venuti, RP, 2019) |
| "Heart failure is the end stage of various heart diseases such as ischemic heart disease, dilated cardiomyopathy, valvular heart disease, congenital heart disease, and hypertensive myocardial damage." | 2.61 | Advances in research on treatment of heart failure with nitrosyl hydrogen. ( An, J; Deng, Y; Guo, Y; Wang, J; Wu, L; Xu, J, 2019) |
| "Nitroxyl (HNO) plays a unique role in cardiovascular physiology by direct post-translational modification of thiol residues on target proteins, specifically SERCA2a, phospholamban, the ryanodine receptor and myofilament proteins in cardiomyocytes." | 2.61 | Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. ( Borentain, M; Cleland, JG; DeSouza, MM; Felker, GM; Kessler, PD; McMurray, JJV; O'Connor, CM; Seiffert, D; Teerlink, JR; Voors, AA, 2019) |
| "Nitroxyl (HNO) is a simple molecule with significant potential as a pharmacological agent." | 2.55 | The chemical biology of HNO signaling. ( Bartberger, MD; Bianco, CL; Fukuto, JM; Toscano, JP, 2017) |
| "Nitroxyl donors have been shown to improve cardiac function in normal and failing dogs, and in isolated cardiomyocytes they increase fractional shortening and Ca(2+) transients, independently from cAMP/PKA or cGMP/PKG signaling." | 2.50 | Nitroxyl (HNO) for treatment of acute heart failure. ( Arcaro, A; Lembo, G; Tocchetti, CG, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 4 (23.53) | 2.80 |
| Authors | Studies |
|---|---|
| Nguépy Keubo, FR | 1 |
| Mboua, PC | 1 |
| Djifack Tadongfack, T | 1 |
| Fokouong Tchoffo, E | 1 |
| Tasson Tatang, C | 1 |
| Ide Zeuna, J | 1 |
| Noupoue, EM | 1 |
| Tsoplifack, CB | 1 |
| Folefack, GO | 1 |
| Kettani, M | 1 |
| Bandelier, P | 1 |
| Huo, J | 1 |
| Li, H | 4 |
| Yu, D | 1 |
| Arulsamy, N | 1 |
| AlAbbad, S | 1 |
| Sardot, T | 1 |
| Lekashvili, O | 1 |
| Decato, D | 1 |
| Lelj, F | 1 |
| Alexander Ross, JB | 1 |
| Rosenberg, E | 1 |
| Nazir, H | 1 |
| Muthuswamy, N | 1 |
| Louis, C | 1 |
| Jose, S | 1 |
| Prakash, J | 1 |
| Buan, MEM | 1 |
| Flox, C | 1 |
| Chavan, S | 1 |
| Shi, X | 1 |
| Kauranen, P | 1 |
| Kallio, T | 1 |
| Maia, G | 1 |
| Tammeveski, K | 1 |
| Lymperopoulos, N | 1 |
| Carcadea, E | 1 |
| Veziroglu, E | 1 |
| Iranzo, A | 1 |
| M Kannan, A | 1 |
| Arunamata, A | 1 |
| Tacy, TA | 1 |
| Kache, S | 1 |
| Mainwaring, RD | 1 |
| Ma, M | 1 |
| Maeda, K | 1 |
| Punn, R | 1 |
| Noguchi, S | 1 |
| Hahn, S | 3 |
| Iwasa, Y | 3 |
| Ling, J | 2 |
| Voccio, JP | 2 |
| Kim, Y | 3 |
| Song, J | 3 |
| Bascuñán, J | 2 |
| Chu, Y | 1 |
| Tomita, M | 1 |
| Cazorla, M | 1 |
| Herrera, E | 1 |
| Palomeque, E | 1 |
| Saud, N | 1 |
| Hoplock, LB | 1 |
| Lobchuk, MM | 1 |
| Lemoine, J | 1 |
| Li, X | 10 |
| Henson, MA | 1 |
| Unsihuay, D | 1 |
| Qiu, J | 1 |
| Swaroop, S | 1 |
| Nagornov, KO | 1 |
| Kozhinov, AN | 1 |
| Tsybin, YO | 1 |
| Kuang, S | 1 |
| Laskin, J | 1 |
| Zin, NNINM | 1 |
| Mohamad, MN | 1 |
| Roslan, K | 1 |
| Abdul Wafi, S | 1 |
| Abdul Moin, NI | 1 |
| Alias, A | 1 |
| Zakaria, Y | 1 |
| Abu-Bakar, N | 1 |
| Naveed, A | 1 |
| Jilani, K | 1 |
| Siddique, AB | 1 |
| Akbar, M | 1 |
| Riaz, M | 1 |
| Mushtaq, Z | 1 |
| Sikandar, M | 1 |
| Ilyas, S | 1 |
| Bibi, I | 1 |
| Asghar, A | 1 |
| Rasool, G | 1 |
| Irfan, M | 1 |
| Li, XY | 1 |
| Zhao, S | 1 |
| Fan, XH | 1 |
| Chen, KP | 1 |
| Hua, W | 1 |
| Liu, ZM | 1 |
| Xue, XD | 1 |
| Zhou, B | 1 |
| Zhang, S | 2 |
| Xing, YL | 1 |
| Chen, MA | 1 |
| Sun, Y | 1 |
| Neradilek, MB | 1 |
| Wu, XT | 1 |
| Zhang, D | 2 |
| Huang, W | 1 |
| Cui, Y | 1 |
| Yang, QQ | 1 |
| Li, HW | 1 |
| Zhao, XQ | 1 |
| Hossein Rashidi, B | 1 |
| Tarafdari, A | 1 |
| Ghazimirsaeed, ST | 1 |
| Shahrokh Tehraninezhad, E | 1 |
| Keikha, F | 1 |
| Eslami, B | 1 |
| Ghazimirsaeed, SM | 1 |
| Jafarabadi, M | 1 |
| Silvani, Y | 1 |
| Lovita, AND | 1 |
| Maharani, A | 1 |
| Wiyasa, IWA | 1 |
| Sujuti, H | 1 |
| Ratnawati, R | 1 |
| Raras, TYM | 1 |
| Lemin, AS | 1 |
| Rahman, MM | 1 |
| Pangarah, CA | 1 |
| Kiyu, A | 1 |
| Zeng, C | 2 |
| Du, H | 1 |
| Lin, D | 1 |
| Jalan, D | 1 |
| Rubagumya, F | 1 |
| Hopman, WM | 1 |
| Vanderpuye, V | 1 |
| Lopes, G | 1 |
| Seruga, B | 1 |
| Booth, CM | 1 |
| Berry, S | 1 |
| Hammad, N | 1 |
| Sajo, EA | 1 |
| Okunade, KS | 1 |
| Olorunfemi, G | 1 |
| Rabiu, KA | 1 |
| Anorlu, RI | 1 |
| Xu, C | 2 |
| Xiang, Y | 1 |
| Xu, X | 1 |
| Zhou, L | 2 |
| Dong, X | 1 |
| Tang, S | 1 |
| Gao, XC | 1 |
| Wei, CH | 1 |
| Zhang, RG | 1 |
| Cai, Q | 1 |
| He, Y | 1 |
| Tong, F | 1 |
| Dong, JH | 1 |
| Wu, G | 1 |
| Dong, XR | 1 |
| Tang, X | 1 |
| Tao, F | 1 |
| Xiang, W | 1 |
| Zhao, Y | 2 |
| Jin, L | 1 |
| Tao, H | 1 |
| Lei, Y | 1 |
| Gan, H | 1 |
| Huang, Y | 1 |
| Chen, Y | 3 |
| Chen, L | 3 |
| Shan, A | 1 |
| Zhao, H | 2 |
| Wu, M | 2 |
| Ma, Q | 1 |
| Wang, J | 5 |
| Zhang, E | 1 |
| Zhang, J | 3 |
| Li, Y | 5 |
| Xue, F | 1 |
| Deng, L | 1 |
| Liu, L | 2 |
| Yan, Z | 2 |
| Wang, Y | 2 |
| Meng, J | 1 |
| Chen, G | 2 |
| Anastassiadou, M | 1 |
| Bernasconi, G | 1 |
| Brancato, A | 1 |
| Carrasco Cabrera, L | 1 |
| Greco, L | 1 |
| Jarrah, S | 1 |
| Kazocina, A | 1 |
| Leuschner, R | 1 |
| Magrans, JO | 1 |
| Miron, I | 1 |
| Nave, S | 1 |
| Pedersen, R | 1 |
| Reich, H | 1 |
| Rojas, A | 1 |
| Sacchi, A | 1 |
| Santos, M | 1 |
| Theobald, A | 1 |
| Vagenende, B | 1 |
| Verani, A | 1 |
| Du, L | 1 |
| Liu, X | 1 |
| Ren, Y | 1 |
| Li, J | 7 |
| Li, P | 1 |
| Jiao, Q | 1 |
| Meng, P | 1 |
| Wang, F | 2 |
| Wang, YS | 1 |
| Wang, C | 3 |
| Zhou, X | 2 |
| Wang, W | 1 |
| Wang, S | 2 |
| Hou, J | 1 |
| Zhang, A | 1 |
| Lv, B | 1 |
| Gao, C | 1 |
| Pang, D | 1 |
| Lu, K | 1 |
| Ahmad, NH | 1 |
| Wang, L | 1 |
| Zhu, J | 2 |
| Zhang, L | 2 |
| Zhuang, T | 1 |
| Tu, J | 1 |
| Zhao, Z | 1 |
| Qu, Y | 1 |
| Yao, H | 1 |
| Wang, X | 5 |
| Lee, DF | 1 |
| Shen, J | 3 |
| Wen, L | 1 |
| Huang, G | 2 |
| Xie, X | 1 |
| Zhao, Q | 1 |
| Hu, W | 1 |
| Zhang, Y | 4 |
| Wu, X | 1 |
| Lu, J | 2 |
| Li, M | 1 |
| Li, W | 2 |
| Wu, W | 1 |
| Du, F | 1 |
| Ji, H | 1 |
| Yang, X | 2 |
| Xu, Z | 1 |
| Wan, L | 1 |
| Wen, Q | 1 |
| Cho, CH | 1 |
| Zou, C | 1 |
| Xiao, Z | 1 |
| Liao, J | 1 |
| Su, X | 1 |
| Bi, Z | 1 |
| Su, Q | 1 |
| Huang, H | 1 |
| Wei, Y | 2 |
| Gao, Y | 2 |
| Na, KJ | 1 |
| Choi, H | 1 |
| Oh, HR | 1 |
| Kim, YH | 1 |
| Lee, SB | 1 |
| Jung, YJ | 1 |
| Koh, J | 1 |
| Park, S | 1 |
| Lee, HJ | 1 |
| Jeon, YK | 1 |
| Chung, DH | 1 |
| Paeng, JC | 1 |
| Park, IK | 1 |
| Kang, CH | 1 |
| Cheon, GJ | 1 |
| Kang, KW | 1 |
| Lee, DS | 1 |
| Kim, YT | 1 |
| Pajuelo-Lozano, N | 1 |
| Alcalá, S | 1 |
| Sainz, B | 1 |
| Perona, R | 1 |
| Sanchez-Perez, I | 1 |
| Logotheti, S | 1 |
| Marquardt, S | 1 |
| Gupta, SK | 1 |
| Richter, C | 1 |
| Edelhäuser, BAH | 1 |
| Engelmann, D | 1 |
| Brenmoehl, J | 1 |
| Söhnchen, C | 1 |
| Murr, N | 1 |
| Alpers, M | 1 |
| Singh, KP | 1 |
| Wolkenhauer, O | 1 |
| Heckl, D | 1 |
| Spitschak, A | 1 |
| Pützer, BM | 1 |
| Liao, Y | 1 |
| Cheng, J | 1 |
| Kong, X | 1 |
| Li, S | 1 |
| Zhang, M | 4 |
| Zhang, H | 1 |
| Yang, T | 2 |
| Dong, Y | 1 |
| Xu, Y | 1 |
| Yuan, Z | 1 |
| Cao, J | 1 |
| Zheng, Y | 1 |
| Luo, Z | 1 |
| Mei, Z | 1 |
| Yao, Y | 1 |
| Liu, Z | 2 |
| Liang, C | 1 |
| Yang, H | 1 |
| Song, Y | 1 |
| Yu, K | 1 |
| Zhu, C | 1 |
| Huang, Z | 1 |
| Qian, J | 1 |
| Ge, J | 1 |
| Hu, J | 2 |
| Wang, H | 2 |
| Liu, Y | 4 |
| Mi, Y | 1 |
| Kong, H | 1 |
| Xi, D | 1 |
| Yan, W | 1 |
| Luo, X | 1 |
| Ning, Q | 1 |
| Chang, X | 2 |
| Zhang, T | 2 |
| Wang, Q | 2 |
| Rathore, MG | 1 |
| Reddy, K | 1 |
| Chen, H | 1 |
| Shin, SH | 1 |
| Ma, WY | 1 |
| Bode, AM | 1 |
| Dong, Z | 1 |
| Mu, W | 1 |
| Liu, C | 3 |
| Gao, F | 1 |
| Qi, Y | 1 |
| Lu, H | 1 |
| Zhang, X | 4 |
| Cai, X | 1 |
| Ji, RY | 1 |
| Hou, Y | 3 |
| Tian, J | 2 |
| Shi, Y | 1 |
| Ying, S | 1 |
| Tan, M | 1 |
| Feng, G | 1 |
| Kuang, Y | 1 |
| Chen, D | 1 |
| Wu, D | 3 |
| Zhu, ZQ | 1 |
| Tang, HX | 1 |
| Shi, ZE | 1 |
| Kang, J | 1 |
| Liu, Q | 1 |
| Qi, J | 2 |
| Mu, J | 1 |
| Cong, Z | 1 |
| Chen, S | 2 |
| Fu, D | 1 |
| Li, Z | 2 |
| Celestrin, CP | 1 |
| Rocha, GZ | 1 |
| Stein, AM | 1 |
| Guadagnini, D | 1 |
| Tadelle, RM | 1 |
| Saad, MJA | 1 |
| Oliveira, AG | 1 |
| Bianconi, V | 1 |
| Bronzo, P | 1 |
| Banach, M | 1 |
| Sahebkar, A | 1 |
| Mannarino, MR | 1 |
| Pirro, M | 1 |
| Patsourakos, NG | 1 |
| Kouvari, M | 1 |
| Kotidis, A | 1 |
| Kalantzi, KI | 1 |
| Tsoumani, ME | 1 |
| Anastasiadis, F | 1 |
| Andronikos, P | 1 |
| Aslanidou, T | 1 |
| Efraimidis, P | 1 |
| Georgiopoulos, A | 1 |
| Gerakiou, K | 1 |
| Grigoriadou-Skouta, E | 1 |
| Grigoropoulos, P | 1 |
| Hatzopoulos, D | 1 |
| Kartalis, A | 1 |
| Lyras, A | 1 |
| Markatos, G | 1 |
| Mikrogeorgiou, A | 1 |
| Myroforou, I | 1 |
| Orkopoulos, A | 1 |
| Pavlidis, P | 1 |
| Petras, C | 1 |
| Riga, M | 1 |
| Skouloudi, M | 1 |
| Smyrnioudis, N | 1 |
| Thomaidis, K | 1 |
| Tsikouri, GE | 1 |
| Tsikouris, EI | 1 |
| Zisimos, K | 1 |
| Vavoulis, P | 1 |
| Vitali, MG | 1 |
| Vitsas, G | 1 |
| Vogiatzidis, C | 1 |
| Chantanis, S | 1 |
| Fousas, S | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Jungen, C | 1 |
| Alken, FA | 1 |
| Eickholt, C | 1 |
| Scherschel, K | 1 |
| Kuklik, P | 1 |
| Klatt, N | 1 |
| Schwarzl, J | 1 |
| Moser, J | 1 |
| Jularic, M | 1 |
| Akbulak, RO | 1 |
| Schaeffer, B | 1 |
| Willems, S | 1 |
| Meyer, C | 1 |
| Nowak, JK | 1 |
| Szczepanik, M | 1 |
| Trypuć, M | 1 |
| Pogorzelski, A | 1 |
| Bobkowski, W | 1 |
| Grytczuk, M | 1 |
| Minarowska, A | 1 |
| Wójciak, R | 1 |
| Walkowiak, J | 1 |
| Lu, Y | 1 |
| Xi, J | 1 |
| Li, C | 1 |
| Chen, W | 2 |
| Hu, X | 1 |
| Zhang, F | 1 |
| Wei, H | 1 |
| Wang, Z | 1 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Sugimura, H | 2 |
| Stefan-van Staden, RI | 1 |
| Yamada, H | 1 |
| Natsume, H | 1 |
| Iwashita, Y | 1 |
| Szodorai, R | 1 |
| Szederjesi, J | 1 |
| Yari, D | 1 |
| Ehsanbakhsh, Z | 1 |
| Validad, MH | 1 |
| Langroudi, FH | 1 |
| Esfandiari, H | 1 |
| Prager, A | 1 |
| Hassanpour, K | 1 |
| Kurup, SP | 1 |
| Mets-Halgrimson, R | 1 |
| Yoon, H | 1 |
| Zeid, JL | 1 |
| Mets, MB | 1 |
| Rahmani, B | 1 |
| Araujo-Castillo, RV | 1 |
| Culquichicón, C | 1 |
| Solis Condor, R | 1 |
| Efendi, F | 1 |
| Sebayang, SK | 1 |
| Astutik, E | 1 |
| Hadisuyatmana, S | 1 |
| Has, EMM | 1 |
| Kuswanto, H | 1 |
| Foroutan, T | 1 |
| Ahmadi, F | 1 |
| Moayer, F | 1 |
| Khalvati, S | 1 |
| Zhang, Q | 2 |
| Lyu, Y | 1 |
| Huang, J | 1 |
| Yu, N | 1 |
| Wen, Z | 1 |
| Hou, H | 1 |
| Zhao, T | 1 |
| Gupta, A | 1 |
| Khosla, N | 1 |
| Govindasamy, V | 1 |
| Saini, A | 1 |
| Annapurna, K | 1 |
| Dhakate, SR | 1 |
| Akkaya, Ö | 1 |
| Chandgude, AL | 1 |
| Dömling, A | 1 |
| Harnett, J | 1 |
| Oakes, K | 1 |
| Carè, J | 1 |
| Leach, M | 1 |
| Brown, D | 1 |
| Cramer, H | 1 |
| Pinder, TA | 1 |
| Steel, A | 1 |
| Anheyer, D | 1 |
| Cantu, J | 1 |
| Valle, J | 1 |
| Flores, K | 1 |
| Gonzalez, D | 1 |
| Valdes, C | 1 |
| Lopez, J | 1 |
| Padilla, V | 1 |
| Alcoutlabi, M | 1 |
| Parsons, J | 1 |
| Núñez, K | 1 |
| Hamed, M | 1 |
| Fort, D | 1 |
| Bruce, D | 1 |
| Thevenot, P | 1 |
| Cohen, A | 1 |
| Weber, P | 1 |
| Menezes, AMB | 1 |
| Gonçalves, H | 1 |
| Perez-Padilla, R | 1 |
| Jarvis, D | 1 |
| de Oliveira, PD | 1 |
| Wehrmeister, FC | 1 |
| Mir, S | 1 |
| Wong, J | 1 |
| Ryan, CM | 1 |
| Bellingham, G | 1 |
| Singh, M | 2 |
| Waseem, R | 1 |
| Eckert, DJ | 1 |
| Chung, F | 1 |
| Hegde, H | 1 |
| Shimpi, N | 1 |
| Panny, A | 1 |
| Glurich, I | 1 |
| Christie, P | 1 |
| Acharya, A | 1 |
| English, KL | 1 |
| Downs, M | 1 |
| Goetchius, E | 1 |
| Buxton, R | 1 |
| Ryder, JW | 1 |
| Ploutz-Snyder, R | 1 |
| Guilliams, M | 1 |
| Scott, JM | 1 |
| Ploutz-Snyder, LL | 1 |
| Martens, C | 1 |
| Goplen, FK | 1 |
| Aasen, T | 1 |
| Gjestad, R | 1 |
| Nordfalk, KF | 1 |
| Nordahl, SHG | 1 |
| Inoue, T | 1 |
| Soshi, S | 1 |
| Kubota, M | 1 |
| Marumo, K | 1 |
| Mortensen, NP | 1 |
| Caffaro, MM | 1 |
| Patel, PR | 2 |
| Uddin, MJ | 1 |
| Aravamudhan, S | 1 |
| Sumner, SJ | 1 |
| Fennell, TR | 1 |
| Gal, RL | 1 |
| Cohen, NJ | 1 |
| Kruger, D | 1 |
| Beck, RW | 1 |
| Bergenstal, RM | 1 |
| Calhoun, P | 1 |
| Cushman, T | 1 |
| Haban, A | 1 |
| Hood, K | 1 |
| Johnson, ML | 1 |
| McArthur, T | 1 |
| Olson, BA | 1 |
| Weinstock, RS | 1 |
| Oser, SM | 1 |
| Oser, TK | 1 |
| Bugielski, B | 1 |
| Strayer, H | 1 |
| Aleppo, G | 1 |
| Maruyama, H | 1 |
| Hirayama, K | 1 |
| Yamashita, M | 1 |
| Ohgi, K | 1 |
| Tsujimoto, R | 1 |
| Takayasu, M | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 1 |
| Buscagan, TM | 1 |
| Rees, DC | 1 |
| Jaborek, JR | 1 |
| Zerby, HN | 1 |
| Wick, MP | 1 |
| Fluharty, FL | 1 |
| Moeller, SJ | 1 |
| Razavi, P | 1 |
| Dickler, MN | 1 |
| Shah, PD | 1 |
| Toy, W | 1 |
| Brown, DN | 1 |
| Won, HH | 1 |
| Li, BT | 1 |
| Shen, R | 1 |
| Vasan, N | 1 |
| Modi, S | 1 |
| Jhaveri, K | 1 |
| Caravella, BA | 1 |
| Patil, S | 1 |
| Selenica, P | 1 |
| Zamora, S | 1 |
| Cowan, AM | 1 |
| Comen, E | 1 |
| Singh, A | 1 |
| Covey, A | 1 |
| Berger, MF | 1 |
| Hudis, CA | 1 |
| Norton, L | 1 |
| Nagy, RJ | 1 |
| Odegaard, JI | 1 |
| Lanman, RB | 1 |
| Solit, DB | 1 |
| Robson, ME | 1 |
| Lacouture, ME | 1 |
| Brogi, E | 1 |
| Reis-Filho, JS | 1 |
| Moynahan, ME | 1 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Papouskova, K | 1 |
| Moravcova, M | 1 |
| Masrati, G | 1 |
| Ben-Tal, N | 1 |
| Sychrova, H | 1 |
| Zimmermannova, O | 1 |
| Fang, J | 1 |
| Fan, Y | 1 |
| Luo, T | 2 |
| Su, H | 1 |
| Tsetseris, L | 1 |
| Anthopoulos, TD | 1 |
| Liu, SF | 1 |
| Zhao, K | 1 |
| Sacan, O | 1 |
| Turkyilmaz, IB | 1 |
| Bayrak, BB | 1 |
| Mutlu, O | 1 |
| Akev, N | 1 |
| Yanardag, R | 1 |
| Gruber, S | 1 |
| Kamnoedboon, P | 1 |
| Özcan, M | 1 |
| Srinivasan, M | 1 |
| Jo, YH | 1 |
| Oh, HK | 1 |
| Jeong, SY | 1 |
| Lee, BG | 1 |
| Zheng, J | 1 |
| Guan, H | 1 |
| Li, D | 2 |
| Tan, H | 1 |
| Maji, TK | 1 |
| J R, A | 1 |
| Mukherjee, S | 1 |
| Alexander, R | 1 |
| Mondal, A | 1 |
| Das, S | 1 |
| Sharma, RK | 1 |
| Chakraborty, NK | 1 |
| Dasgupta, K | 1 |
| Sharma, AMR | 1 |
| Hawaldar, R | 1 |
| Pandey, M | 1 |
| Naik, A | 1 |
| Majumdar, K | 1 |
| Pal, SK | 1 |
| Adarsh, KV | 1 |
| Ray, SK | 1 |
| Karmakar, D | 1 |
| Ma, Y | 2 |
| Gao, W | 1 |
| Ma, S | 1 |
| Lin, W | 1 |
| Zhou, T | 1 |
| Wu, T | 1 |
| Wu, Q | 1 |
| Ye, C | 1 |
| He, X | 1 |
| Jiang, F | 1 |
| Yuan, D | 1 |
| Chen, Q | 1 |
| Hong, M | 1 |
| Chen, K | 1 |
| Hussain, M | 1 |
| Razi, SS | 1 |
| Yildiz, EA | 1 |
| Zhao, J | 1 |
| Yaglioglu, HG | 1 |
| Donato, MD | 1 |
| Jiang, J | 1 |
| Jamil, MI | 1 |
| Zhan, X | 1 |
| Chen, F | 1 |
| Cheng, D | 1 |
| Wu, CT | 1 |
| Utsunomiya, T | 1 |
| Ichii, T | 1 |
| Fujinami, S | 1 |
| Nakajima, K | 1 |
| Sanchez, DM | 1 |
| Raucci, U | 1 |
| Ferreras, KN | 1 |
| Martínez, TJ | 1 |
| Mordi, NA | 1 |
| Mordi, IR | 1 |
| Singh, JS | 1 |
| McCrimmon, RJ | 1 |
| Struthers, AD | 1 |
| Lang, CC | 1 |
| Wang, XW | 1 |
| Yuan, LJ | 1 |
| Yang, Y | 1 |
| Chen, WF | 1 |
| Luo, R | 1 |
| Yang, K | 1 |
| Amarasiri, SS | 1 |
| Attanayake, AP | 1 |
| Arawwawala, LDAM | 1 |
| Jayatilaka, KAPW | 1 |
| Mudduwa, LKB | 1 |
| Ogunsuyi, O | 2 |
| Akanni, O | 1 |
| Alabi, O | 1 |
| Alimba, C | 1 |
| Adaramoye, O | 1 |
| Cambier, S | 1 |
| Eswara, S | 1 |
| Gutleb, AC | 1 |
| Bakare, A | 1 |
| Gu, Z | 1 |
| Cong, J | 1 |
| Pellegrini, M | 1 |
| Palmieri, S | 1 |
| Ricci, A | 1 |
| Serio, A | 1 |
| Paparella, A | 1 |
| Lo Sterzo, C | 1 |
| Jadeja, SD | 1 |
| Vaishnav, J | 1 |
| Mansuri, MS | 1 |
| Shah, C | 1 |
| Mayatra, JM | 1 |
| Shah, A | 1 |
| Begum, R | 1 |
| Song, H | 2 |
| Lian, Y | 1 |
| Wan, T | 1 |
| Schultz-Lebahn, A | 1 |
| Skipper, MT | 1 |
| Hvas, AM | 1 |
| Larsen, OH | 1 |
| Hijazi, Z | 1 |
| Granger, CB | 1 |
| Hohnloser, SH | 1 |
| Westerbergh, J | 1 |
| Lindbäck, J | 1 |
| Alexander, JH | 1 |
| Keltai, M | 1 |
| Parkhomenko, A | 1 |
| López-Sendón, JL | 1 |
| Lopes, RD | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 1 |
| El-Tarabany, MS | 1 |
| Saleh, AA | 1 |
| El-Araby, IE | 1 |
| El-Magd, MA | 1 |
| van Ginkel, MPH | 1 |
| Schijven, MP | 1 |
| van Grevenstein, WMU | 1 |
| Schreuder, HWR | 1 |
| Pereira, EDM | 1 |
| da Silva, J | 1 |
| Carvalho, PDS | 1 |
| Grivicich, I | 1 |
| Picada, JN | 1 |
| Salgado Júnior, IB | 1 |
| Vasques, GJ | 1 |
| Pereira, MADS | 1 |
| Reginatto, FH | 1 |
| Ferraz, ABF | 1 |
| Vasilenko, EA | 1 |
| Gorshkova, EN | 1 |
| Astrakhantseva, IV | 1 |
| Drutskaya, MS | 1 |
| Tillib, SV | 1 |
| Nedospasov, SA | 1 |
| Mokhonov, VV | 1 |
| Nam, YW | 1 |
| Cui, M | 1 |
| Orfali, R | 1 |
| Viegas, A | 1 |
| Nguyen, M | 1 |
| Mohammed, EHM | 1 |
| Zoghebi, KA | 1 |
| Rahighi, S | 1 |
| Parang, K | 1 |
| Patterson, KC | 1 |
| Kahanovitch, U | 1 |
| Gonçalves, CM | 1 |
| Hablitz, JJ | 1 |
| Staruschenko, A | 1 |
| Mulkey, DK | 1 |
| Olsen, ML | 1 |
| Gu, L | 1 |
| Cao, X | 1 |
| Mukhtar, A | 1 |
| Wu, K | 1 |
| Zhang, YY | 1 |
| Zhu, Y | 1 |
| Lu, DZ | 1 |
| Dong, W | 1 |
| Bi, WJ | 1 |
| Feng, XJ | 1 |
| Wen, LM | 1 |
| Sun, H | 1 |
| Qi, MC | 1 |
| Chang, CC | 1 |
| Dinh, TK | 1 |
| Lee, YA | 1 |
| Wang, FN | 1 |
| Sung, YC | 1 |
| Yu, PL | 1 |
| Chiu, SC | 1 |
| Shih, YC | 1 |
| Wu, CY | 1 |
| Huang, YD | 1 |
| Lu, TT | 1 |
| Wan, D | 1 |
| Sakizadeh, J | 1 |
| Cline, JP | 1 |
| Snyder, MA | 1 |
| Kiely, CJ | 1 |
| McIntosh, S | 1 |
| Jiang, X | 1 |
| Cao, JW | 1 |
| Zhao, CK | 1 |
| Yang, R | 1 |
| Zhang, QY | 1 |
| Chen, KJ | 2 |
| Liu, H | 1 |
| He, Z | 1 |
| Chen, B | 1 |
| Wu, J | 1 |
| Du, X | 1 |
| Moore, J | 1 |
| Blank, BR | 1 |
| Eksterowicz, J | 1 |
| Sutimantanapi, D | 1 |
| Yuen, N | 1 |
| Metzger, T | 1 |
| Chan, B | 1 |
| Huang, T | 1 |
| Chen, X | 1 |
| Duong, F | 1 |
| Kong, W | 1 |
| Chang, JH | 1 |
| Sun, J | 1 |
| Zavorotinskaya, T | 1 |
| Ye, Q | 1 |
| Junttila, MR | 1 |
| Ndubaku, C | 1 |
| Friedman, LS | 1 |
| Fantin, VR | 1 |
| Sun, D | 1 |
| Fei, P | 1 |
| Xie, Q | 1 |
| Jiang, Y | 1 |
| Feng, H | 1 |
| Chang, Y | 1 |
| Kang, H | 1 |
| Xing, M | 1 |
| Chen, J | 1 |
| Shao, Z | 1 |
| Yuan, C | 1 |
| Wu, Y | 1 |
| Allan, R | 1 |
| Canham, K | 1 |
| Wallace, R | 1 |
| Singh, D | 1 |
| Ward, J | 1 |
| Cooper, A | 1 |
| Newcomb, C | 1 |
| Nammour, S | 1 |
| El Mobadder, M | 1 |
| Maalouf, E | 1 |
| Namour, M | 1 |
| Namour, A | 1 |
| Rey, G | 1 |
| Matamba, P | 1 |
| Matys, J | 1 |
| Zeinoun, T | 1 |
| Grzech-Leśniak, K | 1 |
| Segabinazi Peserico, C | 1 |
| Garozi, L | 1 |
| Zagatto, AM | 1 |
| Machado, FA | 1 |
| Hirth, JM | 1 |
| Dinehart, EE | 1 |
| Lin, YL | 1 |
| Kuo, YF | 1 |
| Nouri, SS | 1 |
| Ritchie, C | 1 |
| Volow, A | 1 |
| Li, B | 2 |
| McSpadden, S | 1 |
| Dearman, K | 1 |
| Kotwal, A | 1 |
| Sudore, RL | 1 |
| Ward, L | 1 |
| Thakur, A | 1 |
| Kondadasula, SV | 1 |
| Ji, K | 1 |
| Schalk, DL | 1 |
| Bliemeister, E | 1 |
| Ung, J | 1 |
| Aboukameel, A | 1 |
| Casarez, E | 1 |
| Sloane, BF | 1 |
| Lum, LG | 1 |
| Xiao, M | 1 |
| Feng, X | 1 |
| Gao, R | 1 |
| Du, B | 1 |
| Brooks, T | 1 |
| Zwirner, J | 1 |
| Hammer, N | 1 |
| Ondruschka, B | 1 |
| Jermy, M | 1 |
| Luengo, A | 1 |
| Marzo, I | 1 |
| Reback, M | 1 |
| Daubit, IM | 1 |
| Fernández-Moreira, V | 1 |
| Metzler-Nolte, N | 1 |
| Gimeno, MC | 1 |
| Tonchev, I | 1 |
| Heberman, D | 1 |
| Peretz, A | 1 |
| Medvedovsky, AT | 1 |
| Gotsman, I | 1 |
| Rashi, Y | 1 |
| Poles, L | 1 |
| Goland, S | 1 |
| Perlman, GY | 1 |
| Danenberg, HD | 1 |
| Beeri, R | 1 |
| Shuvy, M | 1 |
| Fu, Q | 1 |
| Yang, D | 1 |
| Sarapulova, A | 1 |
| Pang, Q | 1 |
| Meng, Y | 1 |
| Wei, L | 1 |
| Ehrenberg, H | 1 |
| Kim, CC | 1 |
| Jeong, SH | 1 |
| Oh, KH | 1 |
| Nam, KT | 1 |
| Sun, JY | 1 |
| Ning, J | 1 |
| Duan, Z | 1 |
| Kershaw, SV | 1 |
| Rogach, AL | 1 |
| Gao, Z | 1 |
| Wang, T | 1 |
| Li, Q | 1 |
| Cao, T | 1 |
| Guo, L | 1 |
| Fu, Y | 1 |
| Seeger, ZL | 1 |
| Izgorodina, EI | 1 |
| Hue, S | 1 |
| Beldi-Ferchiou, A | 1 |
| Bendib, I | 1 |
| Surenaud, M | 1 |
| Fourati, S | 1 |
| Frapard, T | 1 |
| Rivoal, S | 1 |
| Razazi, K | 1 |
| Carteaux, G | 1 |
| Delfau-Larue, MH | 1 |
| Mekontso-Dessap, A | 1 |
| Audureau, E | 1 |
| de Prost, N | 1 |
| Gao, SS | 1 |
| Duangthip, D | 1 |
| Lo, ECM | 1 |
| Chu, CH | 1 |
| Roberts, W | 1 |
| Rosenheck, RA | 1 |
| Miyake, T | 1 |
| Kimoto, E | 1 |
| Luo, L | 1 |
| Mathialagan, S | 1 |
| Horlbogen, LM | 1 |
| Ramanathan, R | 1 |
| Wood, LS | 1 |
| Johnson, JG | 1 |
| Le, VH | 1 |
| Vourvahis, M | 1 |
| Rodrigues, AD | 1 |
| Muto, C | 1 |
| Furihata, K | 1 |
| Sugiyama, Y | 1 |
| Kusuhara, H | 1 |
| Gong, Q | 1 |
| Song, W | 1 |
| Sun, B | 1 |
| Cao, P | 1 |
| Gu, S | 1 |
| Sun, X | 1 |
| Zhou, G | 1 |
| Toma, C | 1 |
| Khandhar, S | 1 |
| Zalewski, AM | 1 |
| D'Auria, SJ | 1 |
| Tu, TM | 1 |
| Jaber, WA | 1 |
| Cho, J | 2 |
| Suwandaratne, NS | 1 |
| Razek, S | 1 |
| Choi, YH | 1 |
| Piper, LFJ | 1 |
| Watson, DF | 1 |
| Banerjee, S | 1 |
| Xie, S | 1 |
| Lindsay, AP | 1 |
| Bates, FS | 1 |
| Lodge, TP | 1 |
| Hao, Y | 1 |
| Chapovetsky, A | 1 |
| Liu, JJ | 1 |
| Welborn, M | 1 |
| Luna, JM | 1 |
| Do, T | 1 |
| Haiges, R | 1 |
| Miller Iii, TF | 1 |
| Marinescu, SC | 1 |
| Lopez, SA | 1 |
| Compter, I | 1 |
| Eekers, DBP | 1 |
| Hoeben, A | 1 |
| Rouschop, KMA | 1 |
| Reymen, B | 1 |
| Ackermans, L | 1 |
| Beckervordersantforth, J | 1 |
| Bauer, NJC | 1 |
| Anten, MM | 1 |
| Wesseling, P | 1 |
| Postma, AA | 1 |
| De Ruysscher, D | 1 |
| Lambin, P | 1 |
| Qiang, L | 1 |
| Yang, S | 1 |
| Cui, YH | 1 |
| He, YY | 1 |
| Kumar, SK | 1 |
| Jacobus, SJ | 1 |
| Cohen, AD | 1 |
| Weiss, M | 1 |
| Callander, N | 1 |
| Singh, AK | 1 |
| Parker, TL | 1 |
| Menter, A | 1 |
| Parsons, B | 1 |
| Kumar, P | 1 |
| Kapoor, P | 1 |
| Rosenberg, A | 1 |
| Zonder, JA | 1 |
| Faber, E | 1 |
| Lonial, S | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Orlowski, RZ | 1 |
| Wagner, LI | 1 |
| Rajkumar, SV | 1 |
| Li, G | 1 |
| Hou, G | 1 |
| Cui, J | 1 |
| Xie, H | 1 |
| Sun, Z | 1 |
| Fang, Z | 1 |
| Dunstand-Guzmán, E | 1 |
| Hallal-Calleros, C | 1 |
| Hernández-Velázquez, VM | 1 |
| Canales-Vargas, EJ | 1 |
| Domínguez-Roldan, R | 1 |
| Pedernera, M | 1 |
| Peña-Chora, G | 1 |
| Flores-Pérez, I | 1 |
| Kim, MJ | 1 |
| Han, C | 1 |
| White, K | 1 |
| Park, HJ | 1 |
| Ding, D | 1 |
| Boyd, K | 1 |
| Rothenberger, C | 1 |
| Bose, U | 1 |
| Carmichael, P | 1 |
| Linser, PJ | 1 |
| Tanokura, M | 1 |
| Salvi, R | 1 |
| Someya, S | 1 |
| Samuni, A | 1 |
| Goldstein, S | 1 |
| Divya, KP | 1 |
| Dharuman, V | 1 |
| Feng, J | 2 |
| Qian, Y | 1 |
| Cheng, Q | 1 |
| Ma, H | 1 |
| Ren, X | 1 |
| Wei, Q | 1 |
| Pan, W | 1 |
| Guo, J | 1 |
| Situ, B | 1 |
| An, T | 1 |
| Zheng, L | 1 |
| Augusto, S | 1 |
| Ratola, N | 1 |
| Tarín-Carrasco, P | 1 |
| Jiménez-Guerrero, P | 1 |
| Turco, M | 1 |
| Schuhmacher, M | 1 |
| Costa, S | 1 |
| Teixeira, JP | 1 |
| Costa, C | 1 |
| Syed, A | 1 |
| Marraiki, N | 1 |
| Al-Rashed, S | 1 |
| Elgorban, AM | 1 |
| Yassin, MT | 1 |
| Chankhanittha, T | 1 |
| Nanan, S | 1 |
| Sorokina, KN | 1 |
| Samoylova, YV | 1 |
| Gromov, NV | 1 |
| Ogorodnikova, OL | 1 |
| Parmon, VN | 1 |
| Ye, J | 2 |
| Liao, W | 1 |
| Zhang, P | 1 |
| Nabi, M | 1 |
| Cai, Y | 1 |
| Li, F | 1 |
| Alsbou, EM | 1 |
| Omari, KW | 1 |
| Adeosun, WA | 1 |
| Asiri, AM | 1 |
| Marwani, HM | 1 |
| Barral, M | 1 |
| Jemal-Turki, A | 1 |
| Beuvon, F | 1 |
| Soyer, P | 1 |
| Camparo, P | 1 |
| Cornud, F | 1 |
| Atwater, BD | 1 |
| Jones, WS | 1 |
| Loring, Z | 1 |
| Friedman, DJ | 1 |
| Namburath, M | 1 |
| Papirio, S | 1 |
| Moscariello, C | 1 |
| Di Costanzo, N | 1 |
| Pirozzi, F | 1 |
| Alappat, BJ | 1 |
| Sreekrishnan, TR | 1 |
| Volpin, F | 1 |
| Woo, YC | 1 |
| Kim, H | 1 |
| Freguia, S | 1 |
| Jeong, N | 1 |
| Choi, JS | 1 |
| Phuntsho, S | 1 |
| Shon, HK | 1 |
| Domínguez-Zambrano, E | 1 |
| Pedraza-Chaverri, J | 1 |
| López-Santos, AL | 1 |
| Medina-Campos, ON | 1 |
| Cruz-Rivera, C | 1 |
| Bueno-Hernández, F | 1 |
| Espinosa-Cuevas, A | 1 |
| Bulavaitė, A | 1 |
| Dalgediene, I | 1 |
| Michailoviene, V | 1 |
| Pleckaityte, M | 1 |
| Sauerbier, P | 1 |
| Köhler, R | 1 |
| Renner, G | 1 |
| Militz, H | 1 |
| Felker, GM | 2 |
| McMurray, JJV | 2 |
| Cleland, JG | 3 |
| O'Connor, CM | 2 |
| Teerlink, JR | 2 |
| Voors, AA | 2 |
| Belohlavek, J | 1 |
| Böhm, M | 1 |
| Borentain, M | 2 |
| Bueno, H | 1 |
| Cole, RT | 1 |
| DeSouza, MM | 2 |
| Ezekowitz, JA | 1 |
| Filippatos, G | 1 |
| Lang, NN | 1 |
| Kessler, PD | 2 |
| Martinez, FA | 1 |
| Mebazaa, A | 2 |
| Metra, M | 2 |
| Mosterd, A | 1 |
| Pang, PS | 1 |
| Ponikowski, P | 2 |
| Sato, N | 1 |
| Seiffert, D | 2 |
| Greenberg, B | 1 |
| Urey, MA | 1 |
| Tocchetti, CG | 4 |
| Mercurio, V | 1 |
| Maack, C | 2 |
| Parissis, J | 1 |
| Bistola, V | 1 |
| Ikonomidis, I | 1 |
| Triposkiadis, F | 1 |
| Eschenhagen, T | 1 |
| Hamdani, N | 1 |
| Heinzel, FR | 1 |
| Lyon, AR | 1 |
| Manstein, DJ | 1 |
| Metzger, J | 1 |
| Papp, Z | 1 |
| Yilmaz, MB | 1 |
| Anker, SD | 1 |
| Balligand, JL | 1 |
| Bauersachs, J | 1 |
| Brutsaert, D | 1 |
| Carrier, L | 1 |
| Chlopicki, S | 1 |
| de Boer, RA | 1 |
| Dietl, A | 1 |
| Fischmeister, R | 1 |
| Harjola, VP | 1 |
| Heymans, S | 1 |
| Hilfiker-Kleiner, D | 1 |
| Holzmeister, J | 1 |
| de Keulenaer, G | 1 |
| Limongelli, G | 1 |
| Linke, WA | 1 |
| Lund, LH | 1 |
| Masip, J | 1 |
| Mueller, C | 1 |
| Pieske, B | 1 |
| Ristić, A | 1 |
| Ruschitzka, F | 1 |
| Seferović, PM | 1 |
| Skouri, H | 1 |
| Zimmermann, WH | 1 |
| Cowart, D | 2 |
| Venuti, RP | 1 |
| Lynch, K | 1 |
| Guptill, JT | 1 |
| Noveck, RJ | 1 |
| Foo, SY | 1 |
| Guo, Y | 1 |
| Xu, J | 1 |
| Wu, L | 1 |
| Deng, Y | 1 |
| An, J | 1 |
| Sabbah, HN | 1 |
| Wang, M | 1 |
| Daya, S | 1 |
| Gupta, RC | 1 |
| Tunin, RS | 1 |
| Mazhari, R | 1 |
| Takimoto, E | 1 |
| Paolocci, N | 4 |
| Colucci, WS | 1 |
| Kass, DA | 2 |
| Arcaro, A | 1 |
| Lembo, G | 1 |
| Bianco, CL | 1 |
| Toscano, JP | 1 |
| Bartberger, MD | 1 |
| Fukuto, JM | 3 |
| Kemp-Harper, BK | 1 |
| Horowitz, JD | 1 |
| Ritchie, RH | 1 |
| Tian, Y | 2 |
| Zhong, X | 2 |
| Cheng, JL | 1 |
| Switzer, CH | 1 |
| Flores-Santana, W | 1 |
| Mancardi, D | 1 |
| Donzelli, S | 1 |
| Basudhar, D | 1 |
| Ridnour, LA | 1 |
| Miranda, KM | 2 |
| Wink, DA | 3 |
| Gao, WD | 1 |
| Murray, CI | 1 |
| DuMond, JF | 1 |
| Shen, X | 1 |
| Stanley, BA | 1 |
| Foster, DB | 1 |
| King, SB | 1 |
| Van Eyk, JE | 1 |
| Katori, T | 1 |
| Champion, HC | 1 |
| St John, ME | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Ranging, Phase 2b Study of the Safety and Efficacy of Continuous 48-Hour Intravenous Infusions of BMS-986231 in Hospitalized Patients With Heart Failure and Impaired Systoli[NCT03016325] | Phase 2 | 329 participants (Actual) | Interventional | 2017-01-13 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Cross-over Phase 2 Study of Continuous 8-Hour Intravenous Infusions of BMS-986231 in Patients With Heart Failure and Impaired Systolic Function Given a Standard Dose of Loop Diuretic[NCT03730961] | Phase 2 | 23 participants (Actual) | Interventional | 2019-01-17 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Cross-over Phase 2 Study of Continuous 5-Hour Intravenous Infusions of BMS-986231 in Patients With Heart Failure and Impaired Systolic Function[NCT03357731] | Phase 2 | 49 participants (Actual) | Interventional | 2017-11-30 | Completed | ||
| A Phase IIa, 3 Strata Dose-Defining Study Evaluating the Hemodynamic Effects, Safety and Tolerability of CXL-1020 in Patients With Systolic Heart Failure[NCT01096043] | Phase 2 | 69 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| A Phase I/IIa Dose-Escalation Study Evaluating the Safety and Tolerability of CXL-1020 and Specific Effects on Electrocardiographic and Non-Invasive Hemodynamic Parameters in Patients With Chronic Heart Failure[NCT01092325] | Phase 1/Phase 2 | 28 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The change in baseline for ECGs was reported for each arm. (NCT03016325)
Timeframe: to 120 hours
| Intervention | beats/min (Mean) |
|---|---|
| Placebo - Part I | -5.3 |
| BMS-986231 - Part I | -6.8 |
| Placebo - Part II | -7.1 |
| BMS-986231 6 µg/kg/Min - Part II | -5.1 |
| BMS-986231 12 µg/kg/Min - Part II | -6.1 |
| Placebo - Part II (Japan Cohort) | 2.0 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | -13.0 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | -5.2 |
The change in baseline for laboratory assessments was reported for each arm of the Japan cohort only. (NCT03016325)
Timeframe: to 120 hours
| Intervention | µmol/L (Mean) |
|---|---|
| Placebo - Part II (Japan Cohort) | 4.33 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | -1.50 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | 12.40 |
The change in baseline for laboratory assessments was reported for each arm of the Japan cohort only. (NCT03016325)
Timeframe: to 120 hours
| Intervention | mg/L (Mean) |
|---|---|
| Placebo - Part II (Japan Cohort) | 0.18 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | 0.17 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | 0.25 |
The change in baseline for laboratory assessments was reported for each arm of the Japan cohort only. (NCT03016325)
Timeframe: to 120 hours
| Intervention | Fractional Potassium Excretion percent (Mean) |
|---|---|
| Placebo - Part II (Japan Cohort) | 4.88 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | -1.22 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | -12.34 |
The change in baseline for laboratory assessments was reported for each arm of the Japan cohort only. (NCT03016325)
Timeframe: to 120 hours
| Intervention | Fractional Sodium Excretion percent (Mean) |
|---|---|
| Placebo - Part II (Japan Cohort) | 0.02 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | -2.62 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | -5.50 |
The change in baseline for laboratory assessments was reported for each arm of the Japan cohort only. (NCT03016325)
Timeframe: to 120 hours
| Intervention | nmol/L (Mean) |
|---|---|
| Placebo - Part II (Japan Cohort) | 79.38 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | 74.13 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | 131.64 |
The change in baseline for laboratory assessments was reported for each arm of the Main study cohorts only. (NCT03016325)
Timeframe: to 120 hours
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo - Part I | NA |
| BMS-986231 - Part I | NA |
| Placebo - Part II | NA |
| BMS-986231 6 µg/kg/Min - Part II | NA |
| BMS-986231 12 µg/kg/Min - Part II | NA |
The change in baseline for laboratory assessments was reported for each arm of the Main study cohorts only. (NCT03016325)
Timeframe: to 120 hours
| Intervention | x10^12 c/L (Mean) |
|---|---|
| Placebo - Part I | -0.02 |
| BMS-986231 - Part I | 0.02 |
| Placebo - Part II | 0.04 |
| BMS-986231 6 µg/kg/Min - Part II | 0.04 |
| BMS-986231 12 µg/kg/Min - Part II | 0.09 |
The change in baseline for physical measurements was reported for each arm. (NCT03016325)
Timeframe: to 120 hours
| Intervention | kg (Mean) |
|---|---|
| Placebo - Part I | 0.00 |
| BMS-986231 - Part I | 0.10 |
| Placebo - Part II | -2.87 |
| BMS-986231 6 µg/kg/Min - Part II | -2.96 |
| BMS-986231 12 µg/kg/Min - Part II | -1.83 |
| Placebo - Part II (Japan Cohort) | -3.58 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | -3.97 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | -6.08 |
The change in baseline for vital signs was reported for each arm. (NCT03016325)
Timeframe: to 120 hours
| Intervention | beats/min (Mean) |
|---|---|
| Placebo - Part I | -1.8 |
| BMS-986231 - Part I | -9.1 |
| Placebo - Part II | -8.3 |
| BMS-986231 6 µg/kg/Min - Part II | -4.6 |
| BMS-986231 12 µg/kg/Min - Part II | -6.3 |
| Placebo - Part II (Japan Cohort) | -6.7 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | -3.0 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | 3.8 |
The change in baseline for vital signs was reported for each arm. (NCT03016325)
Timeframe: to 120 hours
| Intervention | breaths/min (Mean) |
|---|---|
| Placebo - Part I | -2.6 |
| BMS-986231 - Part I | -3.0 |
| Placebo - Part II | -2.9 |
| BMS-986231 6 µg/kg/Min - Part II | -2.6 |
| BMS-986231 12 µg/kg/Min - Part II | -1.8 |
| Placebo - Part II (Japan Cohort) | -2.3 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | 0.0 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | -1.4 |
The change in baseline for vital signs was reported for each arm. (NCT03016325)
Timeframe: to 120 hours
| Intervention | degrees C (Mean) |
|---|---|
| Placebo - Part I | -0.04 |
| BMS-986231 - Part I | 0.09 |
| Placebo - Part II | 0.04 |
| BMS-986231 6 µg/kg/Min - Part II | 0.00 |
| BMS-986231 12 µg/kg/Min - Part II | -0.05 |
| Placebo - Part II (Japan Cohort) | -0.47 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | -0.27 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | 0.44 |
"Number of participants who discontinued study treatment due to hypotension.~Medical Dictionary for Regulatory Activities (MedDRA) version: 22.0~Included nonserious adverse events with onset time from the start of study treatment, up to and including 120 hours after the start of study treatment and serious adverse events with onset time from the start of study treatment, up to and including 32 days after the start of study treatment.~Hypotension defined as systolic blood pressure (SBP) < 90 mmHg." (NCT03016325)
Timeframe: up to 120 hours (for AEs); up to 32 days (for SAEs)
| Intervention | Participants (Number) |
|---|---|
| Placebo - Part I | 4 |
| BMS-986231 - Part I | 8 |
| Placebo - Part II | 7 |
| BMS-986231 6 µg/kg/Min - Part II | 13 |
| BMS-986231 12 µg/kg/Min - Part II | 16 |
| Placebo - Part II (Japan Cohort) | 0 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | 1 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | 3 |
"Number of participants who experienced an in-study SAE.~Medical Dictionary for Regulatory Activities (MedDRA) version: 22.0 Included serious adverse events with onset time from the start of study treatment, up to and including 32 days after the start of study treatment." (NCT03016325)
Timeframe: 32 days
| Intervention | Participants (Number) |
|---|---|
| Placebo - Part I | 11 |
| BMS-986231 - Part I | 14 |
| Placebo - Part II | 23 |
| BMS-986231 6 µg/kg/Min - Part II | 15 |
| BMS-986231 12 µg/kg/Min - Part II | 15 |
| Placebo - Part II (Japan Cohort) | 1 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | 0 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | 1 |
"Number of participants who experienced an in-study AE.~Medical Dictionary for Regulatory Activities (MedDRA) version: 22.0~Included nonserious adverse events with onset time from the start of study treatment, up to and including 120 hours after the start of study treatment." (NCT03016325)
Timeframe: up to 120 hours
| Intervention | Participants (Number) |
|---|---|
| Placebo - Part I | 31 |
| BMS-986231 - Part I | 39 |
| Placebo - Part II | 48 |
| BMS-986231 6 µg/kg/Min - Part II | 48 |
| BMS-986231 12 µg/kg/Min - Part II | 55 |
| Placebo - Part II (Japan Cohort) | 2 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | 6 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | 6 |
The percentage of participants experiencing SBP < 90 mm Hg (confirmed by a repeated value) up to 6 hours post-treatment was reported for each arm. (NCT03016325)
Timeframe: From start of infusion up to 6 hours post end of infusion
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo - Part I | 6.3 |
| BMS-986231 - Part I | 20.4 |
| Placebo - Part II | 18.3 |
| BMS-986231 6 µg/kg/Min - Part II | 21.1 |
| BMS-986231 12 µg/kg/Min - Part II | 29.2 |
| Placebo - Part II (Japan Cohort) | 0 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | 33.3 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | 50.0 |
The percentage of participants experiencing symptoms of hypotension up to 6 hours post-treatment was reported for each arm. (NCT03016325)
Timeframe: From start of infusion up to 6 hours post end of infusion
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo - Part I | 2.1 |
| BMS-986231 - Part I | 6.1 |
| Placebo - Part II | 1.4 |
| BMS-986231 6 µg/kg/Min - Part II | 2.8 |
| BMS-986231 12 µg/kg/Min - Part II | 8.3 |
| Placebo - Part II (Japan Cohort) | 0 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | 0 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | 0 |
The change in baseline for ECGs was reported for each arm. (NCT03016325)
Timeframe: to 120 hours
| Intervention | msec (Mean) | |||
|---|---|---|---|---|
| PR Interval, Aggregate, msec | QRS Duration, Aggregate, msec | QT Interval, Aggregate, msec | QTcF Interval, Aggregate, msec | |
| BMS-986231 - Part I | -2.3 | -0.1 | 7.2 | -13.9 |
| BMS-986231 12 µg/kg/Min - Part II | 2.0 | 2.7 | -0.3 | -10.3 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | 6.0 | 3.0 | 16.5 | 3.2 |
| BMS-986231 6 µg/kg/Min - Part II | 10.9 | -1.6 | 5.8 | -4.0 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | 10.4 | -2.5 | 5.7 | -8.8 |
| Placebo - Part I | -17.4 | 5.1 | -10.6 | -27.5 |
| Placebo - Part II | -0.1 | 1.6 | 8.7 | -4.0 |
| Placebo - Part II (Japan Cohort) | -1.5 | -3.0 | -30.0 | -24.8 |
The change in baseline for laboratory assessments was reported for each arm of the Main study cohorts only. (NCT03016325)
Timeframe: to 120 hours
| Intervention | g/L (Mean) | |
|---|---|---|
| hemoglobin, g/L | protein, g/L | |
| BMS-986231 - Part I | -0.70 | 2.77 |
| BMS-986231 12 µg/kg/Min - Part II | 1.38 | -0.05 |
| BMS-986231 6 µg/kg/Min - Part II | 0.94 | 0.38 |
| Placebo - Part I | -0.67 | 1.10 |
| Placebo - Part II | 1.20 | 0.57 |
The change in baseline for laboratory assessments was reported for each arm of the Main study cohorts only. (NCT03016325)
Timeframe: to 120 hours
| Intervention | mmol/L (Mean) | ||
|---|---|---|---|
| blood urea nitrogen, mmol/L | urate, mmol/L | potassium, mmol/L | |
| BMS-986231 - Part I | 0.32 | 0.01 | 0.28 |
| BMS-986231 12 µg/kg/Min - Part II | 1.24 | -0.03 | 0.15 |
| BMS-986231 6 µg/kg/Min - Part II | 2.15 | 0.04 | 0.13 |
| Placebo - Part I | 4.01 | 0.06 | 0.19 |
| Placebo - Part II | 1.96 | -0.01 | 0.21 |
The change in baseline for laboratory assessments was reported for each arm of the Main study cohorts only. (NCT03016325)
Timeframe: to 120 hours
| Intervention | U/L (Mean) | ||
|---|---|---|---|
| alanine aminotransferase (ALT), U/L | alkaline phosphatase, U/L | asparate aminotransferase, U/L | |
| BMS-986231 - Part I | -2.73 | 1.65 | -2.77 |
| BMS-986231 12 µg/kg/Min - Part II | -13.07 | -0.49 | -10.00 |
| BMS-986231 6 µg/kg/Min - Part II | 30.36 | 5.43 | 10.81 |
| Placebo - Part I | 148.13 | -1.00 | 214.77 |
| Placebo - Part II | -3.22 | -1.31 | -11.15 |
The change in baseline for laboratory assessments was reported for each arm of the Main study cohorts only. (NCT03016325)
Timeframe: to 120 hours
| Intervention | x10^9 cells/L (Mean) | |
|---|---|---|
| leukocyte, x10^9 c/L | platelet, x10^9 c/L | |
| BMS-986231 - Part I | -1.38 | -5.77 |
| BMS-986231 12 µg/kg/Min - Part II | -0.09 | 1.26 |
| BMS-986231 6 µg/kg/Min - Part II | 0.20 | 3.26 |
| Placebo - Part I | 0.12 | 5.63 |
| Placebo - Part II | -0.20 | 1.84 |
Assess the effect of BMS-986231 on NT-proBNP (N-terminal prohormone of brain natriuretic peptide) (NCT03016325)
Timeframe: 0, 24, 48, 72, 120 hour or discharge; Day 32
| Intervention | pmol/L (Mean) | ||||
|---|---|---|---|---|---|
| 24 hour | 48 hour | 72 hour | 120 hour | Day 32 | |
| BMS-986231 - Part I | -364.46 | -510.51 | -373.86 | -409.53 | -91.61 |
| BMS-986231 12 µg/kg/Min - Part II | -416.91 | -472.32 | -293.94 | -390.21 | -476.86 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | -397.60 | -497.35 | -229.56 | -552.55 | -706.11 |
| BMS-986231 6 µg/kg/Min - Part II | -340.74 | -300.87 | -118.86 | -76.20 | -361.73 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | -165.93 | -251.73 | 9.89 | -379.06 | -343.64 |
| Placebo - Part I | -270.88 | -405.06 | -396.21 | -541.36 | -202.07 |
| Placebo - Part II | -147.96 | -210.87 | -249.26 | -140.60 | -321.73 |
| Placebo - Part II (Japan Cohort) | -129.70 | -329.24 | -433.08 | -434.36 | -556.69 |
"Endpoint was measured by the area under the curve (AUC) of the 11-point Numerical Rating Scale (NRS) obtained at baseline, and Hours 6, 12, 24, 48, and 72.~Participants were asked to report their absolute current severity of dyspnea on an 11-point numerical rating scale (NRS; range 0 to 10).~The numerical rating scale (NRS) was used to assess the degree of dyspnea (breathlessness), measured using an 11-point scale provided by the Sponsor.~A score of 0 represents I am not breathless at all and 10 represents I am the most breathless I can possibly imagine." (NCT03016325)
Timeframe: Hours 6, 12, 24, 48, and 72
| Intervention | Scores on a scale (Mean) | ||||
|---|---|---|---|---|---|
| 6 hour | 12 hour | 24 hour | 48 hour | 72 hour | |
| BMS-986231 - Part I | -1.5 | -2.2 | -2.1 | -2.6 | -3.7 |
| BMS-986231 12 µg/kg/Min - Part II | -1.7 | -2.0 | -2.2 | -2.8 | -3.2 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | -1.3 | -1.4 | -1.2 | -2.0 | -2.0 |
| BMS-986231 6 µg/kg/Min - Part II | -1.7 | -2.4 | -2.9 | -3.4 | -3.9 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | 0.0 | -0.2 | -1.5 | -0.8 | -1.2 |
| Placebo - Part I | -1.5 | -2.1 | -2.0 | -2.8 | -2.9 |
| Placebo - Part II | -1.1 | -1.7 | -2.1 | -2.8 | -3.2 |
| Placebo - Part II (Japan Cohort) | -0.3 | -1.0 | -0.8 | -1.2 | -1.2 |
Baseline = Last non-missing result with a collection date-time less than or on the date-time of the start of infusion of study drug (NCT03016325)
Timeframe: from baseline to Hour 24, 48, and 72
| Intervention | ng/L (Mean) | ||
|---|---|---|---|
| 24 hour | 48 hour | 72 hour | |
| BMS-986231 - Part I | -1.31 | 14.56 | 6.76 |
| BMS-986231 12 µg/kg/Min - Part II | -8.09 | -11.15 | -13.05 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | -7.67 | -8.40 | -15.00 |
| BMS-986231 6 µg/kg/Min - Part II | -3.45 | 8.08 | 5.00 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | 1.33 | 49.50 | 248.00 |
| Placebo - Part I | 4.11 | -0.93 | 6.07 |
| Placebo - Part II | -1.80 | -2.88 | -1.44 |
| Placebo - Part II (Japan Cohort) | -4.67 | -10.67 | -10.50 |
The change in baseline for vital signs was reported for each arm. (NCT03016325)
Timeframe: to 120 hours
| Intervention | mmHg (Mean) | |
|---|---|---|
| systolic blood pressure, mmHg | diastolic blood pressure, mmHg | |
| BMS-986231 - Part I | 0.0 | -1.9 |
| BMS-986231 12 µg/kg/Min - Part II | -8.8 | -1.6 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | -6.2 | -9.3 |
| BMS-986231 6 µg/kg/Min - Part II | -7.9 | -3.4 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | -17.5 | -15.7 |
| Placebo - Part I | -6.8 | -4.0 |
| Placebo - Part II | -4.3 | -4.4 |
| Placebo - Part II (Japan Cohort) | -10.3 | 1.7 |
"Number of participants who died (all- cause and CV related) through Day 182.~Medical Dictionary for Regulatory Activities (MedDRA) version: 22.0~CV=Cardiovascular" (NCT03016325)
Timeframe: through 182 days
| Intervention | Participants (Number) | |
|---|---|---|
| All-cause | CV-related | |
| BMS-986231 - Part I | 3 | 2 |
| BMS-986231 12 µg/kg/Min - Part II | 9 | 4 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | 1 | 0 |
| BMS-986231 6 µg/kg/Min - Part II | 12 | 10 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | 0 | 0 |
| Placebo - Part I | 3 | 3 |
| Placebo - Part II | 11 | 9 |
| Placebo - Part II (Japan Cohort) | 0 | 0 |
"Number of participants who discontinued study treatment, experienced a down-titration (dose reduction) or dose interruption due to decreased blood pressure/hypotension are reported below.~Medical Dictionary for Regulatory Activities (MedDRA) version: 22.0~Included nonserious adverse events with onset time from the start of study treatment, up to and including 120 hours after the start of study treatment and serious adverse events with onset time from the start of study treatment, up to and including 32 days after the start of study treatment.~If the participant experienced systolic blood pressure (SBP) < 95 mm Hg, without symptoms related to hypotension, the measurement was repeated within 15 minutes. If the SBP remained < 95 mm Hg, the dose reduction occurred." (NCT03016325)
Timeframe: up to 120 hours (for AEs); up to 32 days (for SAEs)
| Intervention | Participants (Number) | ||
|---|---|---|---|
| discontinuation | down-titration | interruption | |
| BMS-986231 - Part I | 8 | 9 | 4 |
| BMS-986231 12 µg/kg/Min - Part II | 15 | 25 | 13 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | 3 | 3 | 0 |
| BMS-986231 6 µg/kg/Min - Part II | 13 | 10 | 12 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | 1 | 1 | 0 |
| Placebo - Part I | 4 | 3 | 3 |
| Placebo - Part II | 7 | 9 | 4 |
| Placebo - Part II (Japan Cohort) | 0 | 0 | 0 |
"Number of participants who experienced an in-study Chemistry marked laboratory abnormality (reported in > 5% of total participants).~Medical Dictionary for Regulatory Activities (MedDRA) version: 22.0" (NCT03016325)
Timeframe: to 120 hours
| Intervention | Participants (Number) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| high blood urea nitrogen values | high urate values | high potassium values | high alanine aminotransferase (ALT) values | high alkaline phosphatase values | low protein values | high asparate aminotransferase values | high bilirubin values | high bicarbonate values | low chloride counts | high creatine kinase values | high protein values | high sodium values | low bicarbonate values | low sodium values | low albumin values | low calcium values | |
| BMS-986231 - Part I | 16 | 15 | 5 | 1 | 0 | 9 | 0 | 2 | 2 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| BMS-986231 12 µg/kg/Min - Part II | 18 | 8 | 2 | 2 | 1 | 4 | 1 | 0 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 2 | 2 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| BMS-986231 6 µg/kg/Min - Part II | 23 | 20 | 7 | 2 | 0 | 8 | 2 | 0 | 0 | 4 | 0 | 0 | 0 | 1 | 2 | 1 | 1 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo - Part I | 23 | 10 | 2 | 6 | 5 | 3 | 4 | 2 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Placebo - Part II | 23 | 10 | 6 | 5 | 2 | 3 | 4 | 0 | 0 | 1 | 0 | 2 | 2 | 2 | 0 | 0 | 2 |
| Placebo - Part II (Japan Cohort) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
"Number of participants who experienced an in-study Hematology marked laboratory abnormality (reported in > 5% of total participants).~Medical Dictionary for Regulatory Activities (MedDRA) version: 22.0" (NCT03016325)
Timeframe: to 120 hours
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| high leukocyte counts | low hemoglobin values | low platelet values | low neutrophils values | low leukocyte counts | low hematocrit values | low erythrocytes values | |
| BMS-986231 - Part I | 2 | 5 | 2 | 1 | 1 | 1 | 1 |
| BMS-986231 12 µg/kg/Min - Part II | 3 | 4 | 1 | 0 | 0 | 0 | 0 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| BMS-986231 6 µg/kg/Min - Part II | 4 | 6 | 7 | 1 | 0 | 3 | 3 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Placebo - Part I | 5 | 4 | 4 | 0 | 0 | 1 | 1 |
| Placebo - Part II | 5 | 5 | 2 | 1 | 2 | 1 | 1 |
| Placebo - Part II (Japan Cohort) | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
"Number of participants who experienced an in-study Urinalysis marked laboratory abnormality (reported in > 5% of total participants).~Medical Dictionary for Regulatory Activities (MedDRA) version: 22.0" (NCT03016325)
Timeframe: to 120 hours
| Intervention | Participants (Number) | ||
|---|---|---|---|
| high protein values | high erythrocyte values | high leukocytes values | |
| BMS-986231 - Part I | 11 | 1 | 1 |
| BMS-986231 12 µg/kg/Min - Part II | 17 | 2 | 1 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | 2 | 0 | 0 |
| BMS-986231 6 µg/kg/Min - Part II | 13 | 3 | 2 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | 2 | 0 | 0 |
| Placebo - Part I | 10 | 1 | 0 |
| Placebo - Part II | 16 | 1 | 0 |
| Placebo - Part II (Japan Cohort) | 2 | 0 | 0 |
Percentage of participants with clinically relevant hypotension, defined by systolic blood pressure (SBP) < 90 mm Hg (confirmed by a repeated value < 90 mm Hg) or symptoms of hypotension, up to 6 hours after the end of study drug infusion (NCT03016325)
Timeframe: From start of infusion up to 6 hours post end of infusion
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| clinically relevant hypotension | symptoms of hypotension | confirmed SBP < 90 mmHg | |
| BMS-986231 - Part I | 20.4 | 6.1 | 20.4 |
| BMS-986231 12 µg/kg/Min - Part II | 34.7 | 8.3 | 29.2 |
| BMS-986231 12 µg/kg/Min - Part II (Japan Cohort) | 50.0 | 0 | 50.0 |
| BMS-986231 6 µg/kg/Min - Part II | 21.1 | 2.8 | 21.1 |
| BMS-986231 6 µg/kg/Min - Part II (Japan Cohort) | 33.3 | 0 | 33.3 |
| Placebo - Part I | 8.3 | 2.1 | 6.3 |
| Placebo - Part II | 18.3 | 1.4 | 18.3 |
| Placebo - Part II (Japan Cohort) | 0 | 0 | 0 |
The change in baseline for ECGs was reported for each arm. (NCT03730961)
Timeframe: Day 1, 8 hours post-dose (end of infusion)
| Intervention | beats/min (Mean) |
|---|---|
| BMS-986231 | 0.9 |
| Placebo | 1.6 |
The change in baseline for physical examinations was reported for each arm. (NCT03730961)
Timeframe: Day 1, 8 hours post-dose (end of infusion)
| Intervention | kg (Mean) |
|---|---|
| BMS-986231 | 0.2 |
| Placebo | -0.5 |
The change in baseline for vital signs was reported for each arm. (NCT03730961)
Timeframe: Day 1, 8 hours post-dose (end of infusion)
| Intervention | beats/min (Mean) |
|---|---|
| BMS-986231 | 0.5 |
| Placebo | -0.1 |
The change in baseline for vital signs was reported for each arm. (NCT03730961)
Timeframe: Day 1, 8 hours post-dose (end of infusion)
| Intervention | oxygen saturation percentage (Mean) |
|---|---|
| BMS-986231 | -1.0 |
| Placebo | 0.0 |
Number of participants who experienced an in-study abnormal clinical laboratory event under the category of Hematology, Chemistry or Urinalysis. (NCT03730961)
Timeframe: from first dose to 30 days post-last dose (ca. 5-8 weeks)
| Intervention | Number of participants (Number) |
|---|---|
| BMS-986231 | 0 |
| Placebo | 0 |
Clinically relevant hypotension is defined as systolic blood pressure (SBP) < 90 mmHg or symptomatic hypotension during infusion (NCT03730961)
Timeframe: up to 8 days
| Intervention | Number of participants (Number) |
|---|---|
| BMS-986231 | 8 |
| Placebo | 6 |
Clinically relevant hypotension is defined as systolic blood pressure (SBP) < 90 mmHg or symptomatic hypotension during infusion (NCT03730961)
Timeframe: up to 8 hours
| Intervention | Number of participants (Number) |
|---|---|
| BMS-986231 | 4 |
| Placebo | 0 |
"Summary of urinary concentrations 0-4 hours after furosemide~Ratio = Cumulative Sodium Excretion / Cumulative Furosemide in Urine" (NCT03730961)
Timeframe: 0-4 hours after furosemide
| Intervention | Ratio of Urinary Na:Urinary furosemide (Mean) |
|---|---|
| BMS-986231 | 6.1 |
| Placebo | 10.1 |
"The total volume of urinary output 4 hours after 40 mg furosemide bolus given to participants with HFrEF while on BMS-986231 compared to placebo: absolute difference in total volume and % change from placebo.~Sequence 1: Placebo in period 1, drug in period 2~Sequence 2: Drug in period 1, placebo in period 2" (NCT03730961)
Timeframe: 4 hours
| Intervention | mL (Mean) | ||
|---|---|---|---|
| Sequence 1 | Sequence 2 | Total | |
| BMS-986231 | 900.7 | 1176.7 | 1032.1 |
| Placebo | 1603.3 | 1345.4 | 1480.5 |
The change in baseline for ECGs was reported for each arm. (NCT03730961)
Timeframe: Day 1, 8 hours post-dose (end of infusion)
| Intervention | msec (Mean) | |||
|---|---|---|---|---|
| PR Interval, Aggregate | QRS Duration, Aggregate | QT Interval, Aggregate | QTcF Interval, Aggregate | |
| BMS-986231 | 2.0 | -0.9 | -9.1 | -11.2 |
| Placebo | -2.8 | 2.2 | -7.9 | -5.1 |
The change in baseline for vital signs was reported for each arm. (NCT03730961)
Timeframe: Day 1, 8 hours post-dose (end of infusion)
| Intervention | mmHg (Mean) | |
|---|---|---|
| diastolic blood pressure | systolic blood pressure | |
| BMS-986231 | -14.5 | -28.4 |
| Placebo | -0.6 | -4.9 |
"Secondary efficacy analyses was performed using the randomized population. The FeNa, FeK, furosemide urinary and plasma concentration and the ratio of urinary sodium to urinary furosemide was calculated at each time point over 4-hour urine/plasma collection after a bolus injection of 40 mg furosemide while receiving BMS-986231 or placebo.~Fractional Excretion K = ((Urine Potassium * Plasma Creatinine) / (Plasma Potassium * Urine Creatinine)) * 100" (NCT03730961)
Timeframe: Day 1, predose; 0-4 hours, 4-5 hours, 5-6 hours, 6-7 hours, 7-8 hours
| Intervention | percent of filtered potassium (Mean) | |||||
|---|---|---|---|---|---|---|
| Before start of infusion | 0-4 hours | 4-5 hours | 5-6 hours | 6-7 hours | 7-8 hours | |
| BMS-986231 | 0.4 | 0.5 | 1.1 | 1.2 | 1.1 | 1.0 |
| Placebo | 0.4 | 0.4 | 0.9 | 1.2 | 1.0 | 0.8 |
"Secondary efficacy analyses was performed using the randomized population. The FeNa, FeK, furosemide urinary and plasma concentration and the ratio of urinary sodium to urinary furosemide was calculated at each time point over 4-hour urine/plasma collection after a bolus injection of 40 mg furosemide while receiving BMS-986231 or placebo.~Fractional Excretion Na = ((Urine Sodium * Plasma Creatinine) / (Plasma Sodium * Urine Creatinine)) * 100" (NCT03730961)
Timeframe: Day 1, predose; 0-4 hours, 4-5 hours, 5-6 hours, 6-7 hours, 7-8 hours
| Intervention | percent of filtered sodium (Mean) | |||||
|---|---|---|---|---|---|---|
| Before start of infusion | 0-4 hours | 4-5 hours | 5-6 hours | 6-7 hours | 7-8 hours | |
| BMS-986231 | 0.5 | 0.6 | 4.6 | 5.0 | 3.3 | 1.7 |
| Placebo | 0.6 | 0.7 | 5.4 | 7.0 | 4.7 | 3.3 |
Summary of plasma concentrations by interval. (NCT03730961)
Timeframe: Day 1: 4, 5, 6, 8, 10 hours
| Intervention | ng/mL (Mean) | ||||
|---|---|---|---|---|---|
| 4 hours post-dose | 5 hours post-dose | 6 hours post-dose | 8 hours post-dose | 10 hours post-dose | |
| BMS-986231 | 1605 | 2049 | 1122 | 426.8 | 345.6 |
| Placebo | 63.6 | 2145 | 1146 | 476.6 | 244.3 |
Summary of urine recovery by interval, measured by amount excreted. (NCT03730961)
Timeframe: Day 1, predose, 0-2 hours, 2-4 hours, 4-5 hours, 5-6 hours, 6-7 hours, 7-8 hours, 8-10 hours
| Intervention | mg (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Before start of infusion | 0-2 hours | 2-4 hours | 4-5 hours | 5-6 hours | 6-7 hours | 7-8 hours | 8-10 hours | |
| BMS-986231 | 0.2 | 0.1 | 0.3 | 7.9 | 4.3 | 2.8 | 2.0 | 1.7 |
| Placebo | 0.2 | 0.1 | 0.1 | 8.2 | 3.7 | 2.7 | 1.7 | 1.6 |
"Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:~Mean LV power index" (NCT03357731)
Timeframe: at the end of the 5-hour infusion
| Intervention | watts per square meter (W/m^2) (Mean) |
|---|---|
| Placebo (PBO) | 0.4122 |
| BMS-986231 | 0.3427 |
| Nitroglycerin (NTG) | 0.3568 |
"Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:~Diastolic function" (NCT03357731)
Timeframe: at the end of the 5-hour infusion
| Intervention | cm/sec (Mean) |
|---|---|
| Placebo (PBO) | 7.18 |
| BMS-986231 | 8.07 |
| Nitroglycerin (NTG) | 7.18 |
"Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:~LV global longitudinal strain" (NCT03357731)
Timeframe: at the end of the 5-hour infusion
| Intervention | Percentage of blood pumped from the LV (Mean) |
|---|---|
| Placebo (PBO) | -11.98 |
| BMS-986231 | -11.94 |
| Nitroglycerin (NTG) | -11.36 |
"Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:~LV ejection fraction" (NCT03357731)
Timeframe: at the end of the 5-hour infusion
| Intervention | Percentage of blood pumped from the LV (Mean) |
|---|---|
| Placebo (PBO) | 31.9 |
| BMS-986231 | 32.8 |
| Nitroglycerin (NTG) | 33.5 |
The objective is to evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by stroke volume index (SVI) assessed by echocardiography compared to placebo. (NCT03357731)
Timeframe: at the end of the 5-hour infusion
| Intervention | mL/m^2 (Mean) |
|---|---|
| Placebo (PBO) | 29.545 |
| BMS-986231 | 28.721 |
The objective is to evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by stroke volume index (SVI) assessed by echocardiography compared to NTG. (NCT03357731)
Timeframe: at the end of the 5-hour infusion
| Intervention | mL/m^2 (Mean) |
|---|---|
| BMS-986231 | 28.721 |
| Nitroglycerin (NTG) | 27.811 |
"Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:~Diastolic function" (NCT03357731)
Timeframe: at the end of the 5-hour infusion
| Intervention | Ratio (Mean) | |
|---|---|---|
| E/A ratio | E/e' ratio | |
| BMS-986231 | 0.73 | 7.00 |
| Nitroglycerin (NTG) | 0.71 | 7.81 |
| Placebo (PBO) | 0.80 | 9.42 |
8 reviews available for nitroxyl and Cardiac Failure
| Article | Year |
|---|---|
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Advances in research on treatment of heart failure with nitrosyl hydrogen.
Topics: Calcium; Cardiotonic Agents; Heart Failure; Humans; Hydrogen; Hypertrophy; Inflammation; Myocardial | 2019 |
Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure.
Topics: Acute Disease; Antioxidants; Drug Development; Heart Failure; Humans; Nitrogen Oxides; Stroke Volume | 2019 |
Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure.
Topics: Acute Disease; Antioxidants; Drug Development; Heart Failure; Humans; Nitrogen Oxides; Stroke Volume | 2019 |
Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure.
Topics: Acute Disease; Antioxidants; Drug Development; Heart Failure; Humans; Nitrogen Oxides; Stroke Volume | 2019 |
Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure.
Topics: Acute Disease; Antioxidants; Drug Development; Heart Failure; Humans; Nitrogen Oxides; Stroke Volume | 2019 |
Nitroxyl (HNO) for treatment of acute heart failure.
Topics: Animals; Antioxidants; Free Radicals; Heart Failure; Humans; Myocardial Contraction; Myocardium; Nit | 2014 |
The chemical biology of HNO signaling.
Topics: Aldehyde Dehydrogenase; Animals; Antioxidants; Heart Failure; Humans; Nitric Oxide; Nitrogen Oxides; | 2017 |
Therapeutic Potential of Nitroxyl (HNO) Donors in the Management of Acute Decompensated Heart Failure.
Topics: Animals; Cardiovascular Agents; Clinical Trials as Topic; Heart Failure; Humans; Nitric Oxide; Nitro | 2016 |
[Role of nitroxyl hydrogen on normal and failing heart].
Topics: Heart; Heart Failure; Humans; Hydrogen Bonding; Nitrogen Oxides | 2008 |
The emergence of nitroxyl (HNO) as a pharmacological agent.
Topics: Animals; Heart Failure; Humans; Models, Biological; Myocardial Reperfusion Injury; Nitric Oxide; Nit | 2009 |
4 trials available for nitroxyl and Cardiac Failure
| Article | Year |
|---|---|
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study.
Topics: Acute Disease; Double-Blind Method; Heart Failure; Humans; Nitrogen Oxides; Stroke Volume; Treatment | 2021 |
A Phase 1 Randomized Study of Single Intravenous Infusions of the Novel Nitroxyl Donor BMS-986231 in Healthy Volunteers.
Topics: Adult; Blood Pressure; Cohort Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female | 2019 |
Nitroxyl (HNO): A novel approach for the acute treatment of heart failure.
Topics: Animals; Antioxidants; Dogs; Dose-Response Relationship, Drug; Female; Free Radicals; Heart Failure; | 2013 |
Nitroxyl (HNO): A novel approach for the acute treatment of heart failure.
Topics: Animals; Antioxidants; Dogs; Dose-Response Relationship, Drug; Female; Free Radicals; Heart Failure; | 2013 |
Nitroxyl (HNO): A novel approach for the acute treatment of heart failure.
Topics: Animals; Antioxidants; Dogs; Dose-Response Relationship, Drug; Female; Free Radicals; Heart Failure; | 2013 |
Nitroxyl (HNO): A novel approach for the acute treatment of heart failure.
Topics: Animals; Antioxidants; Dogs; Dose-Response Relationship, Drug; Female; Free Radicals; Heart Failure; | 2013 |
6 other studies available for nitroxyl and Cardiac Failure
| Article | Year |
|---|---|
Stand [Up] and Stand by for New Strategies for Treating Acute Heart Failure.
Topics: Heart Failure; Humans; Nitrogen Oxides; Stroke Volume | 2021 |
The multifaceted mechanisms of nitroxyl in heart failure: inodilator or 'only' vasodilator?
Topics: Cardiotonic Agents; Heart Failure; Humans; Nitrogen Oxides; Vasodilator Agents | 2021 |
Nitroxyl donors for acute heart failure: promising newcomers.
Topics: Heart Failure; Humans; Nitric Oxide Donors; Nitrogen Oxides | 2017 |
Treatments targeting inotropy.
Topics: Acute Disease; Animals; Antioxidants; Calcium; Cardiotonic Agents; Case-Control Studies; Catecholami | 2019 |
Nitroxyl-mediated disulfide bond formation between cardiac myofilament cysteines enhances contractile function.
Topics: Acetates; Actins; Animals; Calcium; Cysteine; Dimerization; Disulfides; Heart Failure; In Vitro Tech | 2012 |
Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: independence from beta-adrenergic signaling.
Topics: Animals; Calcitonin Gene-Related Peptide; Cyclic GMP; Dogs; Heart Failure; Myocardial Contraction; N | 2003 |